PreprintAll rights reservedbioRxiv
Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics
- 1Indian Institute of Technology Kanpur
Related
- Pharmacologic Targeting of ZNF281 Suppresses Metastatic Prostate Cancer Beyond Androgen Receptor Dependence
- Box C/D SNORD116-17 promotes prostate cancer progression by targeting the miR-206/E2F5 axis
- Cognitive fusion targeted biopsy is not inferior to systematic biopsy in metastatic prostate cancer: a single-center, paired study
- Design and Preclinical Evaluation of Two Prostate-Specific Membrane Antigen-Targeting Trifluoroborate Derivatives Suitable for One-Step Radiofluorination
- Prospective Comparison of Cognitive MRI-Targeted Biopsy Under Micro-Ultrasound Guidance Versus MRI/Ultrasound Fusion-Guided Transperineal Biopsy for Clinically Significant Prostate Cancer Detection
BibTeX
@misc{kundu2026targeting,
title = {{Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics}},
author = {S. Kundu and P. Ganguly and L. Varte and S. Mahajan and E. N. Prabhakaran and B. Ateeq},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.759088},
url = {https://www.biorxiv.org/content/10.64898/2026.10.14.759088v1},
}
RIS
TY - UNPB
TI - Targeting TMPRSS2-ERG Fusion-Driven Prostate Cancer using Novel HBS-α-Helicomimics
AU - S. Kundu
AU - P. Ganguly
AU - L. Varte
AU - S. Mahajan
AU - E. N. Prabhakaran
AU - B. Ateeq
PY - 2026
DA - 2026/10/14
PB - bioRxiv
DO - 10.64898/2026.10.14.759088
UR - https://www.biorxiv.org/content/10.64898/2026.10.14.759088v1
ER -